Increased potentiation of 5-fluorouracil induced thymidylate synthase inhibition by 5,10-methylenetetrahydrofolate (arfolitixorin) compared to leucovorin in patients with colorectal liver metastases; The Modelle-001 Trial

被引：0
|
作者：
Helena Taflin [1 ]
Elisabeth Odin [2 ]
Göran Carlsson [1 ]
Bengt Gustavsson [2 ]
Oskar Hemmingsson [1 ]
Yvonne Wettergren [2 ]
Krzysztof Urbanowicz [1 ]
Jacek Turyn [2 ]
Ryszard T. Smolenski [3 ]
Godefridus J. Peters [1 ]
机构：
[1] University of Gothenburg,Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy
[2] Department of Surgery,Region Västra Götaland, Sahlgrenska University Hospital
[3] Umeå University,Department of Diagnostics and Intervention/Surgery
[4] Medical University of Gdansk,Department of Biochemistry
[5] Vrije Universiteit Amsterdam,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers (Amsterdam UMC)
来源：
BJC Reports | / 2卷 / 1期
关键词：
D O I：
10.1038/s44276-024-00111-4
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 38 条
  • [21] Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
    Kemeny, N.
    Capanu, M.
    D'Angelica, M.
    Jarnagin, W.
    Haviland, D.
    Dematteo, R.
    Fong, Y.
    ANNALS OF ONCOLOGY, 2009, 20 (07) : 1236 - 1241
  • [22] DCC protein expression in colorectal cancer (CCR) metastases and response to biochemically-modulated 5-fluorouracil (FU) in patients with low level of thymidylate synthase (TS) protein expression
    Lonardi, S
    Debernardis, D
    Bandelloni, R
    Gallo, L
    Monfardini, S
    Aschele, C
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 229 - 229
  • [23] Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer
    Li, Cong
    Gu, Yangkui
    Zhao, Ming
    Yuan, Yunfei
    Wang, Fenghua
    Wang, Zhiqiang
    Li, Wang
    Luo, Huiyan
    Chen, Cui
    Chen, Gong
    Ding, Peirong
    Wu, Xiaojun
    Lu, Zhenhai
    Pan, Zhizhong
    Xu, Ruihua
    He, Youjian
    Wan, Desen
    Li, Yuhong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1079 - 1087
  • [24] Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer
    Cong Li
    Yangkui Gu
    Ming Zhao
    Yunfei Yuan
    Fenghua Wang
    Zhiqiang Wang
    Wang Li
    Huiyan Luo
    Cui Chen
    Gong Chen
    Peirong Ding
    Xiaojun Wu
    Zhenhai Lu
    Zhizhong Pan
    Ruihua Xu
    Youjian He
    Desen Wan
    Yuhong Li
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1079 - 1087
  • [25] Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer
    Shigeta, Kohei
    Hasegawa, Hirotoshi
    Okabayashi, Koji
    Tsuruta, Masashi
    Ishii, Yoshiyuki
    Endo, Takashi
    Ochiai, Hiroki
    Kondo, Takayuki
    Kitagawa, Yuko
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (04) : 946 - 954
  • [26] Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure
    Sato Y.
    Inaba Y.
    Ura T.
    Nishiofuku H.
    Yamaura H.
    Kato M.
    Takahari D.
    Tanaka T.
    Muro K.
    Journal of Gastrointestinal Cancer, 2018, 49 (2) : 132 - 137
  • [27] RESECTABILITY OF COLORECTAL LIVER METASTASES (CLM) WITH CETUXIMAB PLUS CPT-11/5-FLUOROURACIL (5-FU)/LEUCOVORIN(FA)/OXALIPLATIN (L-OHP) (CPT-11-FFL) AS NEOADJUVANT TREATMENT (POCHER TRIAL)
    Torsello, A.
    Garufi, C.
    Tumolo, S.
    Melucci, E.
    Conti, S.
    Campanella, C.
    Zeuli, M.
    Pizzi, G.
    Tropea, G.
    Sperduti, I
    Ettorre, G. M.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2009, 20
  • [28] Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial)
    Garufi, C.
    Torsello, A.
    Tumolo, S.
    Mottolese, M.
    Melucci, E.
    Campanella, C.
    Zeuli, M.
    Sperduti, I.
    Ettorre, G. M.
    Cognetti, F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 348 - 348
  • [29] CETUXIMAB (CMAB) PLUS CPT-11/5-FLUOROURACIL (5-FU)/LEUCOVORIN(FA)/OXALIPLATIN (L-OHP) (CPT-11-FFL) IN UNRESECTABLE COLORECTAL LIVER METASTASES (CLM): POCHER TRIAL TOXICITY RESULTS
    Torsello, A.
    Garufi, C.
    Tumolo, S.
    Mottolese, M.
    Campanella, C.
    Zeuli, M.
    Sperduti, I
    Pizzi, G.
    Ettorre, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 62 - 63
  • [30] Relations between clinical outcomes and pharmacokinetics of irinotecan, oxaliplatin, and 5-fluorouracil during hepatic artery chronomodulated delivery of intravenous cetuximab in patients with extensive liver metastases from colorectal cancer: A translational study in European trial OPTILIV
    Levi, Francis
    KarabouA, Abdoulaye
    Etienne-Grimaldi, Marie-Christine
    Paintaud, Gilles
    Focan, C. N. J.
    Innominato, Pasquale F.
    Bouchanda, Mohamed
    Milano, Gerard
    Chatelut, Etienne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1234